

NHSBT Finance Report

February 2023

Contents	Page
Executive Summary	2
Financial Performance Headlines	3-4
NHSBT – Summary I&E Statement	5
Divisional I&E statements	6-9
Cash & Debtors	10
Contribution Statement	11

Executive Summary

Revenue Update

Blood and Group Services –We continue to remain confident that the 2022/23 financial plan will be delivered within the agreed resourcing envelope. Since the quarter 3, we have seen a small improvement to the forecast financial position, as further transformation reductions are crystallised. Consequently we head into 2023/24 with a higher cash reserve (c£13m versus a £10m working capital threshold), providing a ring fenced contingency to mitigate underlying risks in Blood and Donor Experience next year.

Looking forward to 2023/24, the budgets have now been finalised and will be presented at the March Board for approval. The proposed budget, based on the 8% price increase agreed at the National Commissioning Group, combined with a £12m non recurring transformation budget, has resulted in a break even position for Blood and Group. However, please note that the outlook for 2023/24 remains extremely challenging with limited headroom, the contingency created utilising the cash carried forward from 2022/23, together with a small reserve built into the plan will provide a buffer against uncertainties.

Organ Donation and Transplantation - The latest forecast for ODT predicts an end of year surplus of £1.2m (against a -£1.8m budget deficit). The current cash flow assumes we will draw down the fully allocated programme funding of £86.3m (which includes stem cells, DCD Hearts and pension funding) and can carry forward our cash reserves into next year (subject to DHSC agreement/contingency versus higher volumes, pay inflation and DCD Hearts run off costs). The outlook for 2023/24 results in an operating deficit, as an increasingly growing cost base is met by flat funding.

Tissue and Eye Services – At M11, the latest view reports a deterioration of the year end position. TES now foresee a contribution shortfall of c£1.9m (versus the Q3 forecast of £1.7m), with the incremental increase driven by higher usage of overtime to maintain service level. This contribution gap is being funded by Blood and Group reserves. An income reset planned for 2023/24, is dependent upon on the Pathway for Corneas and also increased pricing to achieve contribution. However if this plan cannot be fully delivered, the risk to Blood cash reserves remains.

Clinical Services – The most recent view continues to forecast a higher than plan surplus for CS, reporting contribution increases across most business units. However, CBC and Stem Cells are currently being cross-subsidised by other business units, as they report slippages in planned activity. Similarly with Blood, the Clinical Services 2023/24 pricing envelope was approved at the February National Commission Group. The expectation is that the planning volumes and reset prices will ensure that each of the business units achieve their agreed level of contribution.

Plasma for Medicines – the 2022/23 financial plan is being fully funded by a combination of cash reserves and plasma for Diagnostics income. Reductions in transformation expenditure and increased income from activity has resulted in higher cash reserves being carried into 2023/24. These reserves will be utilised and consequently results in a balanced budget for next year. Discussions are still ongoing with NHS England to finalise an SLA which will fully fund collection costs once the funding has been utilised.


Capital Update

The year to date spend against the capital allocation is £6.1m, with a full year forecast of £10.5m (versus £21m originally requested). Following work with the capital leads the indicative plan for 2023/24 totals £21m, which is made up of operational capital for the replacement / replenishment of assets, maintenance of our estate and investment within DDTS including Blood Tech Modernisation.

2022/23 NHSBT Financial Performance Headlines - February 2023


Year to date surplus of £6.2m for NHSBT overall, £4.0m ahead of plan

Blood and Group Net Income & Expenditure (excl. Change Programme and Plasma)




Blood and Group; Blood Supply overspends being predominately driven by higher pay expenditure - detail on page 5 & 6.

Clinical Services Net Income & Expenditure (Business unit contribution)




£0.3m behind plan – operating units are £1.3m ahead of plan. This is more than offset by transformation spend of (-£1.6m).

Organ Donation & Transplantation Net Funding & Expenditure




ODT are reporting £2.5m favourable variance against plan. This is driven by lower activity related expenditure - detail on page 8

Blood and Group Change Programme Full Year Outturn




Full year forecast £9.7m, versus the £17m plan. The difference is mostly due to re-categorisation of Blood Tech Modernisation expenditure to capital and reprofiled Colindale spend.

NHSBT Cash Flow 2022/23



Forecast cash balance at the end of March 2023 is £47m

NHSBT I&E Full Year Outturn



Forecast outturn of the end of March 2023 is £8.1m.

2022/23 NHSBT Financial Performance Headlines – February 2023

Year to Date	£6.2m surplus vs £2.2m budget surplus	Blood/Group	+£3.6m	Lower transformation spend.	
		Plasma	-£0.3m	The adverse position reflects an increase in funding available to c/fwd. into 2023/24, arising from lower than expected overhead costs charged (and with the off-setting benefit) through the ABC contribution statement.	
		Clinical Services	-£0.3m	BAU – business units are reporting £1.3m ahead of plan. Transformation - £1.6m expenditure year to date (budget profiled into M12)	
		OTDT	+ £1.0m	ODT (+£2.5m) – lower activity related expenditure combined with increased funding from devolved nations. TES (-£1.6m) – Cornea income shortfall.	
Full Year Forecast (at Q3)	£8.1m deficit forecast vs £8.1m deficit budget	Blood/Group	-£2.6m	Pressures in Blood Supply, partially offset by Change Programme underspends – detail on 5 & 6.	
		Plasma	-£0.3m	ABC allocation £0.3m lower than budget estimates (carry forward as cash to 2023/24).	
		Clinical Services	+£2.3m	Lower costs due to unfilled vacancies and reduced transformation spend.	
		OTDT	+£0.7m	ODT (+£2.4m) – Lower activity related expenditure. TES (-£1.7m) – Cornea activity lower than plan.	
Cash and Debtors	Cash balance £65m	Debtor Days		18 days – ahead of target (22 days)	
		90+ day overdues		£0.6m (within £0.5m - £1.0m target range).	
		Cash		Cash balance forecast at the end of March 2023 is £47m. Notionally; Blood £13.7m, CS £7.9m, ODT £11.3m, Plasma £14.6m	


Arrow direction indicates the direction of performance vs previous month. Colour demonstrates performance against standards and expectations

NHSBT Summary I&E statement - February 2023

Feb			Blood and Group	WTE		Year to Date			Full Year			Variance
Budget	Actual	Variance		Budget	Actual	Budget	Actual	Variance	Prev. Yr Actual	Budget	Q3 Forecast	
1,036	933	(102)	Programme Funding - Corporate			11,392	10,267	(1,126)	11,461	12,428	11,200	(1,228)
25,271	25,406	135	Blood & Components Income			281,064	280,745	(319)	292,274	306,827	306,427	(400)
280	365	85	Blood Supply Other Income			3,193	3,738	544	3,864	3,512	4,017	505
500	376	(124)	Group Services Income			5,581	5,629	48	5,272	6,091	6,379	288
27,087	27,080	(6)	Blood and Group Income			301,231	300,378	(852)	312,872	328,857	328,023	(834)
(134)	(661)	(527)	Blood Supply Cost of Sales	0	0	315	797	482	(2,305)	0	1,080	1,080
(13,196)	(14,244)	(1,048)	Blood Supply Operations	2,462	2,576	(150,337)	(158,231)	(7,894)	(163,543)	(163,952)	(172,927)	(8,975)
(14,992)	(15,334)	(342)	Group Services	1,222	1,152	(166,860)	(164,209)	2,652	(168,895)	(182,936)	(183,078)	(142)
(1,556)	(1,450)	106	Change Programme	0	35	(15,638)	(6,381)	9,257	(12,213)	(16,999)	(10,753)	6,246
(29,877)	(31,689)	(1,812)	Blood and Group Expenditure	3,685	3,764	(332,520)	(328,024)	4,496	(346,956)	(363,886)	(365,677)	(1,791)
(2,791)	(4,608)	(1,818)	Blood and Group Total	3,685	3,764	(31,290)	(27,645)	3,644	(34,085)	(35,029)	(37,654)	(2,626)
Plasma for Medicine												
1,176	346	(829)	Programme Funding - Plasma			12,931	11,996	(935)	29,483	14,107	8,646	(5,461)
682	1,278	596	Plasma for Diagnostics Income			6,818	8,385	1,567	1	7,500	9,840	2,340
1,857	1,624	(234)	Plasma Funding			19,749	20,381	632	29,484	21,607	18,486	(3,121)
0	0	0	Plasma for Medicine Cost of Sales	0	0	0	0	0	1,076	0		
(851)	(655)	196	Plasma for Medicine	122	149	(9,671)	(10,578)	(907)	(29,484)	(16,493)	(8,673)	2,303
(851)	(655)	196	Plasma Expenditure			(9,671)	(10,578)	(907)	(28,408)	(16,493)	(13,672)	2,821
1,006	969	(38)	Plasma for Medicine Total	122	149	10,078	9,803	(275)	1,076	5,113	4,813	(300)
Clinical Services												
374	347	(27)	Programme Funding - Clinical Services			4,115	3,815	(300)	4,162	4,489	4,162	(327)
5,789	6,186	397	Clinical Services Income			65,550	65,561	10	69,057	72,420	73,269	849
6,163	6,533	370	Clinical Services Income			69,665	69,376	(290)	73,219	76,909	77,431	522
(5,402)	(5,575)	(173)	Clinical Services Operations	803	769	(60,298)	(58,721)	1,577	(59,448)	(65,839)	(65,596)	243
0	(117)	(117)	Clinical Services Change Programme	0	7	0	(1,614)	(1,614)	(1,671)	(3,751)	(2,234)	1,517
(5,402)	(5,692)	(290)	Clinical Services Expenditure			(60,298)	(60,334)	(37)	(61,119)	(69,590)	(67,830)	1,760
761	841	81	Clinical Services Total	803	776	9,367	9,041	(326)	12,101	7,319	9,601	2,282
Organ Donation & Transplantation												
6,665	7,039	374	Programme Funding (DHSC and Other UK Health Authorities)			73,317	77,517	4,199	81,504	79,983	84,539	4,556
170	170	0	Programme Funding - Opt Out			1,871	1,871	0	0	2,041	2,041	0
284	288	4	NHSE Funding			3,121	3,176	55	1,921	3,404	3,640	236
7,119	7,497	378	ODT Income			78,309	82,564	4,254	83,425	85,428	90,220	4,792
(5,615)	(5,720)	(105)	Organ Donation and Transplantation Operations	490	473	(65,150)	(64,262)	888	(63,376)	(71,926)	(70,713)	1,213
(362)	(765)	(403)	Organ Donation and Transplantation Change Programme	30	25	(3,985)	(6,609)	(2,624)	(10,500)	(4,488)	(8,102)	(3,614)
(5,977)	(6,485)	(507)	ODT Expenditure			(69,135)	(70,871)	(1,736)	(73,876)	(76,414)	(78,815)	(2,401)
1,142	1,012	(129)	ODT Total	520	498	9,174	11,693	2,519	9,550	9,015	11,406	2,391
Tissues and Eye Services												
1,696	1,257	(439)	Tissue & Eye Services Income			16,283	14,894	(1,389)	15,062	17,937	16,236	(1,701)
46	42	(5)	Programme Funding - Tissue and Eye Services			508	458	(50)	0	554	500	(54)
1,742	1,299	(443)	TES Income			16,791	15,352	(1,439)	15,062	18,491	16,737	(1,755)
(1,060)	(1,193)	(133)	Tissue and Eye Services Operations	153	150	(11,938)	(12,060)	(122)	(12,468)	(13,043)	(12,975)	68
(1,060)	(1,193)	(133)	TES Expenditure			(11,938)	(12,060)	(122)	(12,468)	(13,043)	(12,975)	68
683	106	(576)	TES Total	153	150	4,853	3,292	(1,561)	2,595	5,449	3,762	(1,687)
NHSBT Summary												
43,968	44,033	65	Income			485,745	488,051	2,306	514,063	531,293	530,897	(396)
(43,167)	(45,713)	(2,546)	Expenditure	5,283	5,336	(483,562)	(481,867)	1,695	(522,826)	(539,426)	(538,969)	457
801	(1,680)	(2,480)	NHSBT Surplus/(Deficit)	5,283	5,336	2,183	6,184	4,001	(8,764)	(8,133)	(8,072)	61

Blood and Group - February 2023

Blood Supply (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Blood and Component Income			281.1	280.7	(0.3)	306.8	306.4	(0.4)
Other Blood Supply Income			3.2	3.7	0.5	3.5	4.0	0.5
Total Income			284.3	284.5	0.2	310.3	310.4	0.1
Cost of Sales - Blood Component Stock Movement			0.3	0.8	0.5	0.0	1.1	1.1
Blood Donation	1,420	1,519	(69.2)	(73.2)	(4.1)	(75.3)	(80.0)	(4.7)
Manufacturing, Testing & Issue	732	738	(60.9)	(63.0)	(2.2)	(66.4)	(68.9)	(2.5)
Logistics	310	320	(20.3)	(21.9)	(1.6)	(22.2)	(24.0)	(1.9)
Total Expenditure	2,462	2,576	(150.0)	(157.4)	(7.4)	(164.0)	(171.8)	(7.9)



Blood Supply Operating Surplus/(Deficit)	2,462	2,576	134.2	127.0	(7.2)	146.4	138.6	(7.8)
---	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------

Group Services (incl. Change Programme)	1,222	1,185	(165.5)	(154.7)	10.8	(181.4)	(176.3)	5.2
--	--------------	--------------	----------------	----------------	-------------	----------------	----------------	------------

Group Services detail on page 6

Blood and Group Surplus/(Deficit)	3,685	3,761	(31.3)	(27.6)	3.6	(35.0)	(37.7)	(2.6)
--	--------------	--------------	---------------	---------------	------------	---------------	---------------	--------------

Year to date, Blood Supply are reporting £7.2m adverse cost variance against plan driven by a combination of factors;

- Impact of the higher than budget pay inflation
- Higher use of overtime and temporary staff in Collections and Manufacturing
- Inflationary fuel pressures and increased usage of couriers

The full year effect of these pressures are reflected in the forecast outturn. Combining these with the planned productivity savings in collections that will no longer be delivered and the latest resourcing plans to increase headcount in response to the ongoing stock challenge, Blood Supply are expected to finish the year significantly higher than budget.

Group Services - February 2023

Group Services (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			11.4	10.3	(1.1)	12.4	11.2	(1.2)
Group Services Income			1.5	1.9	0.3	1.7	1.9	0.2
Medical			1.5	1.6	0.1	1.6	1.7	0.1
Research & Development			2.6	2.1	(0.4)	2.8	2.8	0.0
Total Income			17.0	15.9	(1.1)	18.5	17.6	(0.9)
Chief Executive and Board	4	4	(0.7)	(0.7)	(0.0)	(0.8)	(0.8)	(0.0)
Donor Experience	191	182	(22.2)	(22.1)	0.2	(23.9)	(25.8)	(1.9)
Quality	130	132	(7.9)	(7.6)	0.3	(8.6)	(8.4)	0.3
Estates & Facilities	80	77	(45.0)	(45.4)	(0.4)	(49.0)	(49.7)	(0.7)
Finance	111	99	(6.7)	(6.7)	0.0	(7.3)	(7.5)	(0.2)
Strategy and Transformation	14	11	(0.9)	(1.0)	(0.0)	(1.0)	(1.1)	(0.0)
People	154	155	(10.1)	(10.2)	(0.1)	(11.0)	(11.5)	(0.4)
Digital, Data and Technology Services	301	278	(39.6)	(36.6)	3.0	(44.3)	(40.7)	3.6
Research & Development	47	34	(5.8)	(5.3)	0.5	(6.3)	(6.2)	0.1
Medical	193	178	(16.4)	(16.2)	0.2	(18.0)	(17.4)	0.7
Miscellaneous and Capital Charges	0	0	(11.5)	(12.4)	(0.9)	(12.5)	(14.0)	(1.5)
Total Expenditure	1,222	1,149	(166.9)	(164.2)	2.7	(182.9)	(183.1)	(0.1)
Operating Surplus/(Deficit)	1,222	1,149	(149.9)	(148.3)	1.6	(164.4)	(165.5)	(1.1)
Change Programme	0	35	(15.6)	(6.4)	9.3	(17.0)	(10.8)	6.2
Group Services Surplus/(Deficit)	1,222	1,185	(165.5)	(154.7)	10.8	(181.4)	(176.3)	5.2

Year to date, Group Services (excluding the Change Programme) is reporting a £1.6m positive variance against plan. This predominantly reflects underspends reported in DDTS, driven by unfilled vacancies (23 under established) and the re-categorisation of BTM expenditure to capital.

The latest forecast implies that, this position will deteriorate, with increased pressures profiled into March;

- Estate development works profiled towards in the end of the year (-£0.3m)
- BAU direct marketing catch up and increased activity to support Blood stocks levels (-£2.1m)
- selling of Annual Leave (-£0.4m)

The latest transformation plan is currently sitting at c£9.7m, due to the re-categorisation of Blood Technology Modernisation and the reprofiling of Colindale Estates costs into 2023/24.

Clinical Services - February 2023 (operating contributions - pre ABC analysis)

(£)m	WTE		Year to Date Actual			Full Year Forecast		
	Budget	Actual	Budget	Actual	Variance	Budget	Fcst.	Variance
Red Cell Immunohematology (inc Reagents and IBGRL)								
Income			20.6	20.7	0.1	22.6	22.5	(0.1)
Expenditure			(15.8)	(15.1)	0.7	(17.2)	(16.6)	0.6
RCI - direct contribution	250	235	4.8	5.6	0.8	5.3	5.9	0.6
Histocompatibility & Immunogenetics								
Income			14.5	15.2	0.7	16.0	16.7	0.8
Expenditure			(14.4)	(14.4)	0.0	(15.7)	(16.0)	(0.3)
H&I - direct contribution	179	180	0.2	0.9	0.7	0.3	0.7	0.4
Pathology Total - WTE / direct contribution								
	429	414	5.0	6.4	1.5	5.6	6.6	1.0
Therapeutic Apheresis Services								
Income			10.8	12.5	1.8	11.8	13.5	1.6
Expenditure			(8.6)	(9.5)	(0.9)	(9.4)	(10.4)	(1.0)
TAS - direct contribution	99	100	2.2	3.0	0.8	2.5	3.1	0.6
Cord Blood Bank and British Bone Marrow Registry								
Income - prices			7.0	6.1	(0.9)	7.6	7.0	(0.6)
Expenditure			(3.1)	(2.9)	0.2	(3.4)	(3.1)	0.3
SCGT - direct contribution	46	45	3.9	3.2	(0.6)	4.2	3.9	(0.3)
CBC								
Income			4.0	2.1	(1.9)	4.4	3.3	(1.1)
Expenditure			(3.3)	(3.9)	(0.6)	(3.6)	(3.8)	(0.2)
CBC - direct contribution	37	31	0.7	(1.7)	(2.5)	0.8	(0.5)	(1.3)
Cellular & Molecular Therapies (exc CBC)								
Income			12.7	12.7	(0.0)	14.4	14.0	(0.5)
Expenditure			(9.6)	(8.7)	0.8	(10.4)	(9.8)	0.7
CMT I&E	108	107	3.1	3.9	0.8	4.0	4.2	0.2
CAGT Total - WTE / direct contribution								
	290	283	9.9	8.5	(1.4)	11.4	10.7	(0.7)
Transfusion excl. R&D / Medical (within Group Services)								
	39	36	(1.1)	(0.8)	0.3	(1.2)	(1.4)	(0.2)
DTS Management								
	44	36	(4.4)	(3.6)	0.8	(4.8)	(4.1)	0.7
TOTAL - WTE / Operating Surplus/(Deficit)								
	803	770	9.4	10.5	1.2	11.1	11.8	0.8
Change Programme								
	0	7	0.0	(1.5)	(1.5)	(3.8)	(2.2)	1.5
TOTAL - WTE / Clinical Services Surplus/(Deficit)								
	803	776	9.4	9.0	(0.3)	7.3	9.6	2.3

At the end of February, Clinical Services (pre ABC analysis) is reporting £1.2m ahead of plan (excluding change programme). This is predominately driven by higher income across H&I and TAS combined with vacancies reported within the Division.

Summary by Business Unit:

RCI; driven primarily by unfilled vacancies.

H&I; contribution above plan driven by strong Solid Organ and Diseased Association Investigation activity year to date. The latest forecast implies that the higher income run rate will continue over the remainder of the year, offset by expenditure.


TAS; year to date, TAS are reporting favourable activity variances in Photopheresis and Red Cell exchange, resulting in a positive position against plan. The forecast expects activity to remain in line with plan for the final months of the year.

CBC; adverse position against plan due to slippages in high value contracts. The income position looks to improve as the forecast expects a further £1.0m to be received in March.

Cord Blood Bank and Bone Marrow Registry; Both cord blood issues and BBMR harvest behind plan. The latest forecast does not expect Cord activity to achieve plan generating a worsening year end position.

CMT; reduced income relating to ACT projects being delayed into 2023/24, however, this is more than offset by reduced non pay and vacancies through CMT.

Income growth in Clinical Services



Note: Excludes Medical and R&D funding.

Organ Donation and Transplant – February 2023

ODT I&E (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			63.6	66.4	2.8	69.4	72.5	3.1
Other UK Health Authorities Funding			11.6	12.9	1.4	12.6	14.1	1.5
NHSE Funding			3.1	3.2	0.1	3.4	3.6	0.2
Total Funding			78.3	82.6	4.3	85.4	90.2	4.8
Operating Expenditure	490	473	(65.1)	(64.3)	0.9	(71.9)	(70.7)	1.2
Transformation	30	25	(4.0)	(6.6)	(2.6)	(4.5)	(8.1)	(3.6)
Total Expenditure	520	498	(69.1)	(70.9)	(1.7)	(76.4)	(78.8)	(2.4)

ODT Surplus/(Deficit)	520	498	9.2	11.7	2.5	9.0	11.4	2.4
------------------------------	------------	------------	------------	-------------	------------	------------	-------------	------------

Direct contribution to Group Services						(10.8)	(10.8)	0.0
--	--	--	--	--	--	---------------	---------------	------------

ODT Deficit (funded by cash)						(1.8)	0.6	2.3
-------------------------------------	--	--	--	--	--	--------------	------------	------------

The ODT budget envelope for 2022/23 is based on flat funding from DHSC. The resulting deficit at operational level (£1.8m).

At Q3, the forecast reported a small surplus of c£0.6m, predominately driven by an incremental increase in funding from the devolved nations combined with lower than plan activity. Since Q3, this surplus has increased further (+£0.6m), driven by the reprofiling of transformational spend into 2023/24.

Going into 2023/24 the underlying deficit is set to increase further, reflecting incremental uplifts to inflation versus flat funding over the SR21 period. Discussions are on-going with DHSC to confirm how this operating deficit will be funded c£3.1m.

Tissue and Eye Services – February 2023

Year to date, TES are reporting an income shortfall against plan, primarily driven by lower Cornea issues. Latest forecasts imply this will deteriorate further, resulting in a full year contribution shortfall of c£1.9m – with the incremental pressure driven by higher usage of overtime to maintain service.

TES I&E (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Per Act.	Bud.	Act.	Var.	Budget	Fcst.	Variance
Income				15.4	(1.4)	18.5	16.7	(1.8)
Cost of Sales			(0.5)	(0.5)	0.0	(0.5)	(0.5)	0.0
Expenditure	153	150	(11.5)	(11.6)	(0.1)	(12.5)	(12.5)	0.1
Surplus/(Deficit)	153	150	4.9	3.3	(1.6)	5.4	3.8	(1.7)

Plasma for Medicine - February 2023

Plasma for Medicine (£)m	WTE		Year to Date			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			12.9	12.0	(0.9)	14.1	8.6	(5.5)
Plasma for Diagnostics Income			6.8	8.4	1.6	7.5	9.8	2.3
Expenditure	122	149	(9.7)	(10.6)	(0.9)	(16.5)	(13.7)	2.8
Programme Surplus/(Deficit)	122	149	10.1	9.8	(0.3)	5.1	4.8	(0.3)

For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.

The 2022/23 budget envelope estimated a group service contribution of £5.1m, however, ABC analysis/allocation has resulted in an overhead allocation of £4.8m. The balance (£0.3m) will be treated as increased funding carried forward into 2023/24.

Cash Flow – as at February 2023

	Actual Apr-22 £k	Actual May-22 £k	Actual Jun-22 £k	Actual Jul-22 £k	Actual Aug-22 £k	Actual Sep-22 £k	Actual Oct-22 £k	Actual Nov-22 £k	Actual Dec-22 £k	Actual Jan-23 £k	Actual Feb-23 £k	Forecast Mar-23 £k	Total £k
Opening bank balance	64,676	72,432	75,293	69,908	89,346	85,291	85,549	78,791	69,852	70,006	70,314	64,750	64,676
Receipts													
Debtors & Other Receipts	33,604	39,970	34,671	34,788	36,027	37,197	40,547	37,162	34,382	40,097	41,146	42,026	451,617
Revenue Cash Limit	0	0	0	23,833	5,958	5,958	5,958	5,958	5,958	0	0	17,875	71,500
Revenue Cash Limit - Pensions Uplift	0	0	0	3,680	920	935	935	935	935	935	935	990	11,200
Revenue Cash Limit - DCD Hearts	0	0	0	0	0	0	0	0	0	0	0	3,600	3,600
Capital Cash Limit	0	0	0	3,000	0	0	0	0	0	2,000	0	5,500	10,500
Total Receipts	33,604	39,970	34,671	65,301	42,905	44,090	47,440	44,055	41,276	43,032	42,081	69,992	548,417
Payments													
Staff Expenses	6,743	21,016	21,338	21,413	20,986	23,460	24,359	22,692	22,247	22,195	22,521	35,286	264,256
Other Revenue Payments	18,359	15,949	18,378	24,022	25,932	19,396	18,999	30,232	17,557	20,282	23,777	37,169	270,053
Capital Charges Less DH Credit Due	0	0	0	0	0	0	10,437	0	0	0	0	10,437	20,874
Capital Payments	746	144	340	427	42	975	403	70	1,317	249	1,346	4,440	10,500
Total Payments	25,848	37,109	40,055	45,863	46,961	43,832	54,198	52,995	41,121	42,725	47,644	87,332	565,683
Closing bank balance	72,432	75,293	69,908	89,346	85,291	85,549	78,791	69,852	70,006	70,314	64,750	47,410	47,410

Debtor Days (Target is 22 days)	17	14	13	18	17	19	17	14	19	21	18	
YTD BPPC By Value % (Target is 95%)	86.9%	91.1%	93.5%	94.6%	93.4%	93.7%	93.8%	93.6%	93.6%	93.8%	93.7%	
YTD BPPC By Number % (Target is 95%)	92.8%	93.1%	93.3%	93.5%	93.4%	93.3%	93.2%	93.0%	93.1%	93.1%	92.9%	



Overdue Debtors NBS/ODT £000's	1-30 Days overdue £000's	31-60 Days overdue £000's	61-90 Days overdue £000's	>90 Days overdue £000's	Total Overdue £000's
Total Overdue Debtors	5,745	972	198	618	7,533

Notional Split	£m
Blood	13.7
Clinical Services	7.9
ODT	11.3
Plasma	14.6
NHSBT Total	47.4

Top 5 > 90 days Overdue Debtors £000's	Dec-22		Jan-23	
	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
BARTS HEALTH NHS TRUST	102	380	144	232
KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST	51	76	51	76
SOUTH AFRICAN BONE MARROW REGISTRY			27	38
HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST	35	49	27	30
GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST			21	38
IMPERIAL COLLEGE HEALTHCARE NHS TRUST	101	403		
	50	164		
Total 5 Overdue Debtors	339	1,073	270	414
Other Debtors	300	5,758	348	7,119
Total Overdue Debtors	639	6,831	618	7,533

>90 DAYS OVERDUE	Profile by Month													
	Actual Apr-22 £000s	Actual May-22 £000s	Actual Jun-22 £000s	Actual Jul-22 £000s	Actual Aug-22 £000s	Actual Sep-22 £000s	Actual Oct-22 £000s	Actual Nov-22 £000s	Actual Dec-22 £000s	Actual Jan-23 £000s	Actual Feb-23 £000s	Actual Mar-23 £000s		
Target Range Between £0.5m and £1.0m														
Ledger Balance at month end	330	413	686	680	536	922	709	673	612	639	618			

Contribution Statement– as at February 2023

Post allocation of costs via the ABC model

Year to date Actual £m	Blood & Components inc. R&D	Plasma	Pathology		CAGT				TES	ODT	NHSBT
			RCI	H&I	CMT	CBC	SCDT	TAS			
Income/Funding											
Prices	284.0	0.0	19.6	13.2	12.2	0.0	3.8	12.1	14.9	0.0	359.8
Central Funding from DHAs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.4	12.4
Grant in Aid (DHSC Funding)	8.8	12.1	0.2	1.7	0.1	0.0	2.3	0.1	0.6	67.3	93.2
Other	6.0	8.4	1.0	0.5	0.4	2.1	0.1	0.4	0.0	3.7	22.6
Total Income/Funding	298.8	20.5	20.8	15.3	12.8	2.2	6.2	12.6	15.5	83.5	488.1
Expenditure											
Variable Costs	(33.8)	(0.7)	(1.7)	(3.7)	(2.1)	(1.5)	(0.3)	(3.8)	(2.5)	(3.2)	(53.2)
Variable Contribution	264.9	19.8	19.1	11.6	10.7	0.7	5.9	8.9	13.0	80.3	434.9
Direct Costs	(121.5)	(7.0)	(12.2)	(7.5)	(6.6)	(2.5)	(3.4)	(5.5)	(10.1)	(63.8)	(239.9)
Direct Contribution	143.5	12.9	6.9	4.1	4.1	(1.7)	2.5	3.4	2.9	16.5	195.0
Direct Support Costs	(101.5)	(2.8)	(5.1)	(2.0)	(4.4)	(0.9)	(1.6)	(1.3)	(3.2)	(10.0)	(132.9)
Total Allocated Costs	(256.8)	(10.4)	(19.0)	(13.2)	(13.1)	(4.8)	(5.3)	(10.6)	(15.8)	(77.0)	(425.9)
Total Unallocated Costs	(22.8)	(1.2)	(1.7)	(1.2)	(1.2)	(0.4)	(0.5)	(0.9)	(1.4)	(7.2)	(38.4)
Operating Net Surplus / (Deficit)	19.2	8.9	0.1	1.0	(1.5)	(3.1)	0.3	1.1	(1.7)	(0.8)	23.7
Transformation	(6.4)	(2.9)	(0.5)	(0.3)	(0.3)	(0.1)	(0.2)	(0.3)	-	(6.6)	(17.5)
Net Surplus / (Deficit) Inc Transformation	12.8	5.9	(0.3)	0.7	(1.8)	(3.1)	0.2	0.8	(1.7)	(7.4)	6.2
Budget	10.3	5.9	(0.8)	0.2	(2.8)	(0.7)	1.0	0.4	(0.5)	(10.8)	2.2
Variance	2.5	0.1	0.4	0.5	1.0	(2.4)	(0.8)	0.4	(1.2)	3.4	4.0
RAG	G	G	G	G	G	R	R	G	R	G	G

Notes;

Blood at "Green" but results from the reduced change programme plan.

CBC – adverse position against plan due to slippages in high value contracts

Stem Cell and Donation – reporting red as BBMR income and CBB issues are behind plan.

TES – reporting red reflecting lower cornea activity.